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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
magnetic stimulation is an effective treatment for women with urinary incontinence.
STUDY DESIGN: Review of three published, randomized controlled trials (two double-blind
and one single blinded), all English language.
DATA SOURCES: The three randomized controlled trials that were used for this review were
found using PubMed and EBSCOhost. Articles were selected based on relevance and that the
outcomes of the studies mattered to patients.
OUTCOME(S) MESURED: Improvement of urinary incontinence measured by pad-tests and
questionnaires.
RESULTS: The results of the But study suggest that magnetic stimulation is not much more
effective when compared to the control. Gilling et al. demonstrated that there was a statistically
significant improvement in the active arm at 8-wks for 20-min pad test, #pads/day, PFM
strength, 24-h pad test, I-QOL and KHQ scores. Although p-values suggest improvement,
comparing changes in each variable from baseline between groups using ANOVA showed no
statistically significant difference in any outcome measure at 8 weeks or 6 months. Wallis et al.
demonstrated that there were no statistically significant differences in the outcome measures
between baseline and 12 weeks for the treatment and control groups. On the subjective measure
there was a statistically significant difference between the active and control groups (p=0.04).
CONCLUSIONS: The results of these three randomized controlled trials suggest that magnetic
stimulation is not much more effective than a placebo in the treatment of urinary incontinence.
KEY WORDS: Urinary incontinence, magnetic stimulation
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INTRODUCTION
Urinary incontinence (UI) is involuntary loss of urine. UI is a common problem in older
adults and there are three types of urinary incontinence: stress, urge and overflow. Stress
incontinence is most common in women and results from increased intra-abdominal pressure.
This paper evaluates three randomized controlled trials (RCTs) comparing the efficacy of
magnetic stimulation as a treatment for urinary incontinence.
This topic/question is relevant to patients and PA practice because it is common, costly
and accounts for a significant amount of healthcare visits each year. The prevalence of urinary
incontinence increases with age. The prevalence of urinary incontinence in women ranges from
25-51%. Prevalence of UI in women in nursing homes is 60-78%. 30-60% of pregnant women
report UI1. $20 billion was spent on UI in 2000 and cost has nearly doubled in the past decade1.
In 1998 there were 522,240 office visits with UI as primary diagnosis for female Medicare
beneficiaries2.
Continence depends upon both intact micturition physiology (including lower urinary
tract, pelvic, and neurologic components) and an intact functional ability to toilet oneself.
Successful toileting depends upon ready access to toilet facilities, the motivation to maintain
dryness, sufficient mobility and manual dexterity, and the cognitive ability to recognize and react
appropriately to sensations of bladder filling. About 50% of affected women have stress
incontinence, with mixed-stress and urge next common, followed by urge incontinence. Stress
incontinence is caused by inadequate pelvic support and decreased estrogen. Urge incontinence
is the most common form in older adults1.
The usual methods of treatment are lifestyle modifications, behavioral therapy, adjunctive
treatments, pharmacologic therapy, and surgery. Lifestyle modifications include: dietary
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changes, monitoring fluid intake, avoiding caffeine and alcohol, smoking cessation, and weight
loss. Behavioral therapy consists of bladder training (frequent voiding, training of CNS and
pelvic mechanisms to inhibit urgency) and pelvic muscle exercises to strengthen muscular
urethral closure mechanism and biofeedback. Adjunctive measures include: pads, protective
garments and pessaries. Pharmacologic therapy available: Antimuscarinics, Duloxetine,
OnabotulinumtoxinA3.
Magnetic stimulation devices are thought to stimulate pelvic muscle contractions and/or
modulate detrusor contractions, which are necessary for urinary continence. This method of
treatment is being proposed because of the limited efficacy of current treatment modalities3.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not magnetic
stimulation is an effective treatment for women with UI.
METHODS
The studies included are three randomized controlled trials (two double-blind and one
single-blinded). The population studied was women with urinary incontinence. The intervention
was magnetic stimulation. Comparisons: The treatment group receiving magnetic stimulation to
the experimental group who received a placebo (non-functioning magnets). Outcomes
measured: improvement of urinary incontinence measured by pad-tests and questionnaires.
Key words used in the searches were “urinary incontinence” and “magnetic stimulation.”
All articles were published in English and in peer-reviewed journals. This author searched
articles via PubMed and EBSCOhost. The reviewed articles were selected based on relevance
and that the outcomes of the studies mattered to patients (POEMs). The inclusion criteria
included: women with urinary incontinence. Exclusion criteria included: implanted electronic
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equipment, concurrent use of drugs to manage UI, pelvic floor surgery, and pregnancy.
Summary statistics were reported using: p values, RBI, ABI, NNT.
Table 1: Demographics and Characteristics of included studies
Study
Type
#
Age Inclusion
Exclusion
Pts (yrs) criteria
criteria
4
But
Double- 55 >18 Women with UI, Implanted electronic
(2003) blind
y/o
>18 y/o, not
devices, urolithiasis,
RCT
pregnant, not
bladder infection,
physically or
tumor, recent
mentally
urethral/continence
disabled.
surgery; taking
anticholinergics, BB
or diuretics.
Gilling5 Double- 70 >20 Women >20 y/o, incontinence/pelvic
(2009) blind
y/o
sxs of or
floor surgery, grade 3
RCT
confirmed UI,
or 4 pelvic prolapse,
ambulatory, live pregnancy, drugs for
home,
bladder dysfunction,
neurologically
internal electronic
normal, healthy, medical devices,
normal UA,
pelvic or lower limb
stable detrusor
metallic prosthesis
function on
urodynamics
Wallis6 Single- 122 >60 Women >60
implanted electronic
(2012) blinded
y/o
y/o, live at
device, symptomatic
RCT
home, UI
UTI, drugs for UTI
symptoms Q
last 4 weeks,
week x 6 mos.
scheduled for pelvic
floor or GYN surgery
within next 3 months

W/D Intervention
3

Magnetic
stimulation

15

Magnetic
stimulation

21

Magnetic
stimulation

OUTCOMES MEASURED
But study outcomes measured were: urine frequency/loss, nocturia, and PFM
contractions. The outcomes were measured by: number of pads used, pad weight, volume
voided charts, power/duration of PFM contractions measured with perineometer, patient report
by visual analog scale4.

Brandtonies, Magnetic Stimulation for UI 4	
  
Gilling et al Outcomes measured were reduction of urinary leakage and quality of life
which were measured by: 3-day bladder diary, 20 min. provocative pad-test with predetermined
bladder volume, and 24 hour pad test, incontinence quality of life questionnaire (I-QOL) scores,
Kings Health Questionnaire (KHQ) scores, CMV score, peritron perineometry score, and PFX
perineometry score5.
Wallis et al. Outcomes measured were cessation of incontinence, frequency and severity
of symptoms, which were measured by: 24-hour pad test, BFLUTS-SF, incontinence severity
index, bothersomeness visual analog scale, and 24-hour bladder diary6.
RESULTS
The three studies reviewed compared magnetic stimulation to a placebo. All trials were
completed in women with urinary incontinence.
The But4 study was a randomized, double blind, placebo controlled trial that randomized
55 subjects into an active group (30 patients) and placebo group (22 patients). Each patient in
the active group was given a Pulsegen device, which produced a pulsating magnetic field, to
wear day and night for 2 months. Of the 55 participants who entered the trial, 52 completed the
study (5% loss to follow-up). “Worst-case” analysis was not done on participants lost to follow
up. There was no statistically significant difference between the participants in the active and
placebo groups as determined by the Mann-Whitney U test (P>0.05). 55.8 years was the average
age of the women in the study, 40.4% had mixed incontinence, 42.3% has urge incontinence and
17.3% had stress incontinence. After 2 months of continuous magnetic stimulation with the
Pulsegen device, the active group had a statistically significant decrease in daytime frequency
(P=0.048), decrease in nocturia (P=0.0057), decrease in number of pads used (P=0.0031),
decrease in pad weight (P=0.014), increased power of PFM (pelvic floor muscle contractions)
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(P=0.0071), and length of PFM contractions (P=0.038). The active group reported a 56.3%
improvement in UI symptoms by a visual analog scale, which was statistically significant when
compared to the placebo (P=0.00012). The placebo group had a statistically significant decrease
in nocturia (P=0.0035). The placebo group reported a 26.3% improvement in symptoms by a
visual analog scale. 79% (EER) of participants in active group and 22.7% (CER) of participants
in placebo group evaluated success of magnetic stimulation as “excellent” or “good.” The
placebo had a statistically significant lower success rate than the active group (P=0.0022). Table
2 shows the treatment effect of magnetic stimulation on urinary incontinence. Relative benefit
increase (RBI) was calculated to be a 2.48%. Absolute benefit increase (ABI) was calculated to
be 56.3%. Numbers needed to treat (NNT) was calculated as 2, indicating that 2 patients need to
be treated to see one or more positive outcomes4.
Table 2: Treatment effect of Pulsegen magnetic stimulation on urinary incontinence
CER

EER

RBI

ABI

NNT

P

22.7%

79%

2.48%

56.3%

2

0.0022

The Gilling5 et al. was also a double blind, randomized controlled trial that randomized
35 women with urodynamically confirmed stress UI into either the active or sham groups. The
women in the active group were treated with the NeoControl chair and received 3 sessions per
week for 6 weeks. Of the 70 women who were enrolled in the study, only 55 completed (21.4%
loss to follow-up). “Worst case” analysis was not done on participants lost to follow-up. The
participants were evaluated at baseline, 8-weeks, and 6 months. The primary outcome measure
was a change in the 20-minute pad test from baseline to 8-weeks. Table 3 shows the treatment
effect of the NeoControl chair on SUI. In the active group there was a statistically significant
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improvement at 8-weeks for the 20-minute pad test (p<0.001), number of pads used per day
(p<0.01), PFM strength, 24-hour pad test (p<0.01), I-QOL (urinary incontinence quality of life
scale) (p<0.001) and KHQ (kings health questionnaire) (p<0.001) scores. In the placebo group
there was a statistically significant improvement at 8-weeks for the 24-hour pad test and I-QOL
score. Statistical significance was defined as a 0.67 standard deviation difference in reduction
between the groups. 17% (EER) of patients in the active group and 9% (CER) of patients in the
placebo group did not leak on repeat urodynamics at 8-weeks. RBI was calculated to be 0.89%.
ABI was calculated to be 8%. NNT was calculated as 135.
Table 3: Treatment effect of NeoControl chair on stress urinary incontinence
CER

EER

RBI

ABI

NNT

9%

17%

0.89%

8%

13

The study by Wallis6 et al. was a single blinded, randomized, placebo controlled trial of
static magnetic stimulation on women aged 60 and older with UI for at least 6 months. 122
subjects entered the trail and 101 completed the trial (17.2% loss to follow up). “Worst case”
analysis was not done on subjects lost to follow-up. 50 participants were randomly assigned to
the active group and 51 to the placebo group. The active group received an undergarment
containing 15 static magnets that they were to wear at least 12 hours per day for 3 months. The
primary outcome was incontinence cessation measured by 24-hour pad test (P=0.09). Frequency
and severity of symptoms were the secondary outcomes, which were measured by BFLUTS-SF
(Bristol Female Lower Urinary Tract Symptoms questionnaire) (P>0.05), Incontinence Severity
Index (P=0.59), Bothersomeness Visual Analog scale (P=0.21) and 24-hour bladder diary
(P>0.05). Data was gathered at baseline and 12 weeks later. Table 4 shows the treatment effect
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of static magnetic stimulation on UI. There were no statistically significant differences between
the active and placebo groups in any of the measured outcomes from baseline to 12-weeks.
However, the subjects that adhered to the protocol 85% of the time, the active group had a
statistically significant decrease in the Bothersomeness score at 12-weeks (P=0.02). RBI was
calculated to be 0.57%. ABI was calculated to be 20.5%. NNT was calculated to be 56.
Table 4: Treatment effect of static magnetic stimulation on UI
CER

EER

RBI

ABI

NNT

36%

56.5%

0.57%

20.5%

5

There appears to be few adverse events and magnetic stimulation was generally well
tolerated and safe in the three articles reviewed. The But4 study reported that one patient
experienced acute onset of pre-existent lumbar-ischialgia, which resolved with removal of the
Pulsegen device. Two other patients in the But4 study experienced a pulsating sensation in the
lower abdomen and perineum.
DISCUSSION
This selective evidence based medicine review investigated three randomized controlled
trials to determine whether or not magnetic stimulation is an effective treatment for women with
UI. None of the studies selected provided definitive evidence that magnetic stimulation is an
effective treatment modality for UI.
The results of the But4 study are generalizable to female patients with UI and suggest that
magnetic stimulation with the Pulsegen may be a good conservative treatment for urinary
incontinence. However, the RBI of 2.48% is small and suggests that the treatment is not much
more effective when compared to the placebo. ABI suggests that 56.3% of patients will have
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improvement of urinary incontinence symptoms if they use magnetic stimulation instead of
nothing. Some limitations of the study include: patient compliance, small sample size, unequal
distribution between active and placebo groups, and inability of study to determine the rate of the
placebo effect4.
The results of the Gilling et al. study are generalizable to women with UI described in my
clinical question. Although p-values suggest statistically significant improvement of UI with
NeoControl chair, comparing changes in each variable from baseline between groups using
ANOVA showed no statistically significant difference in any outcome measure at 8 weeks or 6
months. Calculated RBI of 0.89% and ABI of 8% are small values and suggest that the treatment
is not more effective when compared to placebo. Some limitations of the study include: small
sample size, 21.4% loss to follow-up, unforeseen effects of pelvic floor muscle training5.
The results of the Wallis et al. study are generalizable to women with UI. There were no
statistically significant differences in the outcome measures between baseline and 12 weeks for
the treatment and control groups. On the subjective measure (when patients were asked at the
end of study whether their UI had improved) there was a statistically significant difference
between the active and control groups (p=0.04). However, once sensitivity analysis was done,
the benefit was no longer statistically significant. The calculated RBI of 0.57% and ABI of
20.5% are small and suggest that the treatment is not more effective when compared to placebo.
Some limitations of the study include: poor patient compliance because of garment issues
(uncomfortable, visible under clothing), placebo effect, and difficulty blinding because the
magnets attracted metal objects6.
CONCLUSIONS
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In theory, magnetic stimulation appears to be a promising treatment modality for UI.
However, based on the results of reviewed studies, magnetic stimulation does not appear to be an
effective treatment modality for UI. Statistical significance was only attained by the But4 study,
which did not perform sensitivity analysis to rule out placebo effect. I can therefore conclude
that the reviewed studies demonstrated no definitive evidence that magnetic stimulation is an
effective treatment for UI. Due to the pervasiveness of UI in women, future study of noninvasive treatments such as magnetic stimulation for treatment is warranted.
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